Clinical Trials Browser

Carcinoma in Situ × Genitourinary × 90 days × Clear all

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05951179 2026-05-18

ADVANCED-2

Phase 2 Recruiting

131 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Phase 1/2 Recruiting

350 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-04-23

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase 2 Recruiting

16 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT07322263 2026-04-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Phase 2 Recruiting

174 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07480356 2026-03-18

ADVANCED-3

Phase 3 Not yet recruiting

284 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1 Completed

15 enrolled 21 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04452591 2026-03-16

BOND-003

Phase 3 Active not recruiting

190 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

Clinical Trials

INTerpath-011

ADVANCED-2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

ADVANCED-3

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

BOND-003